Skip to main content

Table 6 Drug-resistant profiles of 684 drug-resistant tuberculosis cases stratified by resistance to isoniazid and rifampicin

From: Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study

 

Other resistant TB

(n = 136)

Hr-TB

(n = 316)

RR-TB

(n = 53)

MDR-TB

(n = 179)

Total

(n = 684)

Resistant to

 INH

0 (0.0%)

316 (100.0%)

0 (0.0%)

179 (100.0%)

495 (72.4%)

 RIF

0 (0.0%)

0 (0.0%)

53 (100.0%)

179 (100.0%)

232 (33.9%)

 Rfb

0 (0.0%)

0 (0.0%)

36 (67.9%)

110 (61.5%)

146 (21.3%)

 EMB

9 (6.6%)

27 (8.5%)

1 (1.9%)

94 (52.5%)

131 (19.2%)

 PZA

16 (11.8%)

6 (1.9%)

1 (1.9%)

66 (36.9%)

89 (13.0%)

 Km

4 (2.9%)

2 (0.6%)

1 (1.9%)

24 (13.4%)

31 (4.5%)

 Am

3 (2.2%)

2 (0.6%)

1 (1.9%)

21 (11.7%)

27 (3.9%)

 Cm

11 (8.1%)

2 (0.6%)

1 (1.9%)

20 (11.2%)

34 (5.0%)

 Sm

64 (47.1%)

43 (13.6%)

2 (3.8%)

59 (33.0%)

168 (24.6%)

 Lfx

34 (25.0%)

4 (1.3%)

1 (1.9%)

34 (19.0%)

73 (10.7%)

 Mfx

29 (21.3%)

3 (0.9%)

1 (1.9%)

31 (17.3%)

64 (9.4%)

 Ofx

32 (23.5%)

4 (1.3%)

1 (1.9%)

34 (19.0%)

71 (10.4%)

 Pto

0 (0.0%)

25 (7.9%)

0 (0.0%)

20 (11.2%)

45 (6.6%)

 Cs

0 (0.0%)

1 (0.3%)

0 (0.0%)

5 (2.8%)

6 (0.9%)

 PAS

2 (1.5%)

29 (9.2%)

0 (0.0%)

27 (15.1%)

58 (8.5%)

Resistance to any FQsa

34 (25.0%)

4 (1.3%)

1 (1.9%)

36 (20.1%)

75 (11.0%)

Resistance to any SLIDsb

12 (8.8%)

3 (0.9%)

1 (1.9%)

26 (14.5%)

42 (6.1%)

  1. Abbreviations: INH isoniazid, RIF rifampicin, Rfb rifabutin, EMB ethambutol, PZA pyrazinamide, Km kanamycin, Am amikacin, Cm capreomycin, Sm streptomycin, Lfx levofloxacin, Mfx moxifloxacin, Ofx ofloxacin, Pto prothionamide, Cs cycloserine, PAS para-aminosalicylic acid, FQs fluoroquinolones, SLIDs second-line injectable drugs
  2. aAny fluoroquinolones refer to levofloxacin, moxifloxacin, or ofloxacin
  3. bAny second-line injectable drugs refer to kanamycin, amikacin, or capreomycin